As DOT1L emerged as an essential molecular drug target in acute leukemias harboring a KMT2A-fusion protein, small-molecule inhibitors targeting DOT1L were developed to reverse aberrantly expressed leukemic transcriptional programs in those leukemias. This evidence concerns the gene KMT2A and acute leukemia.